celgene
Celgene Buys The Rights To BeiGene’s Checkpoint Inhibitor
BeiGene will acquire Celgene’s commercial operations in China and exclusive license to Celgene’s China cancer commercial portfolio.
BeiGene will acquire Celgene’s commercial operations in China and exclusive license to Celgene’s China cancer commercial portfolio.